First-in-Human Study of INCB062079, a Fibroblast Growth Factor Receptor 4 Inhibitor, in Patients with Advanced Solid Tumors

INTRODUCTION: Fibroblast growth factor receptor (FGFR)-4/FGF19 pathway dysregulation is implicated in hepatobiliary and other solid tumors. INCB062079, an oral, selective, FGFR4 inhibitor, inhibits growth in FGF19/FGFR4-driven liver cancer models. METHODS: This was a two-part, phase I study (NCT0314...

Descripción completa

Detalles Bibliográficos
Autores principales: Harding, James J., Jungels, Christiane, Machiels, Jean-Pascal, Smith, David C., Walker, Chris, Ji, Tao, Jiang, Ping, Li, Xin, Asatiani, Ekaterine, Van Cutsem, Eric, Abou-Alfa, Ghassan K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2023
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10042765/
https://www.ncbi.nlm.nih.gov/pubmed/36787089
http://dx.doi.org/10.1007/s11523-023-00948-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10042765/
https://www.ncbi.nlm.nih.gov/pubmed/36787089
http://dx.doi.org/10.1007/s11523-023-00948-8

Ejemplares similares